Headaches are a common symptom of a stressful lifestyle, your body not feeling well and other issues. While headaches can be dealt with easily, migraines are not so easy to handle. Migraines are a type of headache that feels like severe throbbing and pulsing sensation, almost like you are hearing your own heartbeat in your brain, usually on one side of the brain. Many people believe that migraines are not that big of a deal because you just have to deal with the pain, but that is not all migraine is, some people find it very difficult to do their daily tasks as they experience dizzying spells, nausea and extreme sensitivity to light and sound! These attacks can last hours and make it difficult for people to go about their daily lives as well. While there are medications available for migraine patients, these medications need time to take effect, so you may be in a lot of pain, but there are not many quick reliefs you can have in place other than learning the symptoms of a migraine attack and taking medication before it happens. But a new approval by the FDA may change this!

The U.S. Food and Drug Administration (FDA) has approved Symbravo, a new medicine to treat acute migraine attacks in adults. This means adults can now use Symbravo to get relief from their migraine symptoms. The FDA's decision was based on the results of three big studies, called Phase 3 trials. These trials involved over 21,000 migraine attacks, so the FDA has a lot of information about how well Symbravo works and how safe it is. The FDA only approves medicines that have been shown to be both safe and effective through a thorough testing process.

Importance of New Treatment Option

"Migraine attacks can happen suddenly and really mess up people's lives. It's estimated that over 39 million people in the U.S. alone get migraines," said Herriot Tabuteau, M.D., CEO of Axsome Therapeutics told US News. This shows how common migraines are and how important it is to have good treatments. "Symbravo gives patients and doctors a new option that can quickly stop a migraine attack, keep it away, and let people get back to their normal activities, all with just one dose." Having a medicine that can give fast and long-lasting relief from migraine pain is a big deal for millions of people. This new treatment is a real step forward in how we treat migraines.

Symbravo Trial Results, How Was It Approved

The trials took place in 3 steps, the Momentum trial study focused on people whose migraines had moderate to severe pain. The results showed that a lot more people taking Symbravo felt pain-free two hours after taking the medicine compared to those who took a placebo which is a dummy pill. Even better, many people felt relief for up to 24 and even 48 hours after just one dose. This long-lasting relief is really important for people with migraines because it means they can get back to their normal lives without worrying about the pain coming back. The study also looked at how many people were free from their worst symptom, like sensitivity to light or sound, or nausea. Symbravo worked better than the placebo in this area too.

While the intercept trial looked at people who took Symbravo when their migraine pain was still mild. Even when the pain was just starting, Symbravo was effective. The results were similar to the MOMENTUM trial, with many people getting pain relief and relief from their worst symptoms. Treating migraines early is often better because it can stop the pain from getting really bad.

And lastly the Movement trial which was to see how safe the medication is when people take it regularly. This study followed 706 people who had at least two migraines a month. The most common side effects people experienced were sleepiness and dizziness. While these side effects are important to know about, the study showed that Symbravo is generally safe for people to use on a regular basis.

Australia issued a health advisory warning travellers and healthcare providers about counterfeit batches of a rabies vaccine that have reportedly been circulating in India since November 1, 2023. The alert has raised concerns for anyone who may have received the vaccine while travelling or living in the country.

This Is What The Australian Advisory Says:

The warning was issued on December 22 by the Australian Technical Advisory Group on Immunisation. It flagged counterfeit batches of the rabies vaccine Abhayrab. While the vaccine is not supplied or used in Australia, the advisory notes that Australians or other travellers who were vaccinated in India could still be at risk.

The advisory clearly states that people who may have received the counterfeit vaccine might not be fully protected against rabies. As a precaution, it recommends that they receive replacement doses using a rabies vaccine that is registered and approved for use in Australia.

As it can be difficult to verify whether a dose was genuine or fake, the advisory takes a cautious approach. It says that anyone who received Abhayrab in India on or after November 1, 2023, should be considered as potentially having been given a counterfeit vaccine. Such individuals should be offered replacement doses as per Australian guidelines.

Why rabies protection is critical

Rabies is a viral zoonotic disease that attacks the central nervous system. In humans, it is most commonly transmitted through the bite of an infected dog. According to the World Health Organization (WHO), once rabies reaches the central nervous system and symptoms begin to appear, the disease is fatal in almost all cases.

India continues to bear a significant burden of the disease. WHO estimates suggest that rabies causes between 18,000 and 20,000 deaths every year in the country. India alone accounts for about 36 percent of rabies deaths globally, making effective vaccination and timely treatment especially critical.

Vaccine manufacturer responds

Abhayrab is manufactured by the Human Biologicals Institute, which is a division of Hyderabad-based Indian Immunologicals Limited. Responding to the advisory, the company said that it had proactively identified an issue in January related to a specific batch of the vaccine, as reported by Scroll.

According to the company, the issue involved Batch Number KA 24014, which was found in the marketplace with packaging that differed from the original. Indian Immunologicals Limited said it immediately informed Indian regulators and has been working closely with regulatory authorities and law enforcement agencies to address the issue. A formal complaint has also been lodged to support an investigation.

The company stressed that every batch of vaccine it produces is tested and released by the Central Drugs Laboratory under the Government of India before being made available for public use.

Broader concerns around medical quality

The advisory also comes at a time when India-made medical products have faced scrutiny abroad. In recent years, deaths allegedly linked to Indian-manufactured cough syrups were reported in countries like Gambia and Uzbekistan. Separately, Indian-made eye drops were suspected to be linked to infections in Sri Lanka.

Read: After Coldrif, WHO Bans 2 More Drugs, But This Is Not the Only Death from Indian Cough Syrup

Indian Immunologicals Limited, however, reiterated its commitment to safety and quality. It noted that Abhayrab has been manufactured since 2000, with over 210 million doses supplied in India and more than 40 countries. The company said the vaccine holds nearly 40 percent of the market share and assured healthcare professionals and the public that supplies made through authorized distributors are safe and meet quality standards.

Millie Bobby Brown has built an impressive career, all while quietly managing a few health concerns along the way. From becoming a household name through Netflix’s hugely popular Stranger Things to leading films like Enola Holmes, the Gen Z actor (now a married mother of one) has made a strong mark in Hollywood. What many people may not realise is that her work has, at times, been shaped by a hearing-related condition. Brown has lived with hearing loss for most of her life, a fact that often goes unnoticed.

Millie Bobby Brown Reveals Having Unilateral Deafness

Brown first spoke publicly about her hearing condition in a 2017 interview with Variety, where she shared that she has had hearing loss in one ear since birth. Even early in her career, she was clear that she would not allow it to stand in the way of her passion for performing. “I just started to sing, and if I sound bad I don’t care, because I’m just doing what I love,” she said at the time. “You don’t have to be good at singing. You don’t have to be good at dancing or acting. If you enjoy it and it makes you happy, you should do it.”

While Brown rarely focuses on her hearing loss, she has spoken about how it affects her daily life. In a conversation with Call Her Daddy host Alex Cooper, she explained that certain sounds, like loud chewing, do not bother her because she can mostly hear herself when she eats. She also shared that her husband, Jake Bongiovi, whom she married in 2022, sometimes jokes that she has “selective hearing.” In reality, she says sounds often feel “muffled, like being underwater.” Brown admitted that she does miss important moments, including hearing directors call out “action” or “cut” on set.

What Is Unilateral Deafness?

Unilateral hearing loss happens when hearing is affected in one ear while the other ear functions normally. Even with hearing in one ear, this condition can make it difficult to understand speech clearly and to identify where sounds are coming from.

The level of hearing loss in one ear can range from mild to severe. When there is little to no hearing at all in one ear, it is described as severe or profound hearing loss, also known as single-sided deafness. Unilateral hearing loss may be present at birth, develop gradually, or appear suddenly. Depending on the cause, options such as hearing aids or cochlear implants may help improve hearing, according to the Cleveland Clinic.

Unilateral Deafness: What Are The Symptoms?

Many symptoms of unilateral hearing loss are similar to those seen with hearing loss in both ears. You may:

• Ask people to repeat what they’ve said
• Increase the volume on your television, laptop, or phone
• Struggle to follow conversations, especially in noisy places like restaurants or busy workplaces
• If hearing is affected in only one ear, tinnitus, or ringing, may occur on that side alone. You may also notice that you tend to rely more on one ear when speaking on the phone or listening to others.
• Although unilateral hearing loss often develops slowly, it can also happen suddenly. If you experience a sudden loss of hearing in one ear, it’s important to seek medical advice promptly.

What Causes Unilateral Hearing Loss?

Doctors do not yet fully understand all the reasons why hearing loss occurs in just one ear. Causes can differ between adults and children. In children, hearing loss may be linked to genetics or infections. Possible causes include:

• Noise-related hearing damage
• Certain inherited conditions, such as neurofibromatosis Type 2, which can lead to acoustic neuromas in one ear
• Head injuries
• Traumatic brain injury (TBI)

Unilateral Hearing Loss: Is There Treatment Available?

According to the American Academy of Audiology, treatment depends on the underlying cause and the severity of the hearing loss. Available options may include:

• Hearing aids: These are typically worn to support sound perception when one ear is affected
• Contralateral routing of signal (CROS) devices: This setup uses two devices. One acts as a microphone on the non-hearing side and sends sound to a hearing aid worn on the functioning ear
• Cochlear implants: These may help restore hearing in the affected ear and improve speech understanding and sound awareness
• Bone-anchored hearing aids: These devices transmit sound from the non-hearing ear to the hearing ear through bone conduction
• Frequency modulation (FM) systems: FM systems use radio signals to send sound directly from a microphone to a receiver, such as a hearing aid worn on the non-hearing ear

In what researchers are calling an important scientific advance, a team in the US has shown through animal experiments that Alzheimer’s disease may be reversible, overturning a belief that has shaped medical thinking for more than 100 years. For generations, the neurodegenerative condition was considered permanent and progressive. The findings, published in Cell Reports Medicine, are based on multiple preclinical mouse models as well as examinations of human Alzheimer’s brain tissue.

The study found that preserving a healthy balance of NAD, a molecule central to cellular energy production, could both prevent and reverse Alzheimer’s-related damage. NAD plays a key role in brain function and is now seen as a major contributor to the disease process. Researchers also observed that NAD levels drop much more sharply in the brains of people with Alzheimer’s, a pattern that was mirrored in mouse models of the condition.

Don't Miss: Taking Tramadol? Scientists Warn It May Cause More Harm Than Relief

Alzheimer’s Disease Can Be Reversed, New Study Shows

“We were extremely encouraged by what we observed,” said Andrew A. Pieper, the study’s senior author and Director of the Brain Health Medicines Center at the Harrington Discovery Institute, University Hospitals, as per Sciencedirect. “By restoring the brain’s energy balance, we saw both structural and functional recovery in mice with advanced Alzheimer’s.”

Pieper noted that the effect appeared consistently across two very different mouse models, each driven by separate genetic mechanisms linked to Alzheimer’s in humans. “Seeing recovery in models caused by distinct genetic pathways strengthens the case that restoring NAD balance in the brain could have real therapeutic potential for patients,” he said.

For the study, researchers examined mice engineered to carry genetic mutations known to cause Alzheimer’s disease in people. One group of mice carried multiple human mutations affecting amyloid processing, while the second group carried a human mutation in the tau protein.

After confirming that brain NAD levels dropped sharply in both human Alzheimer’s tissue and mouse models, the team tested whether stopping this decline before symptoms appeared could prevent disease, and whether restoring NAD levels after the disease had progressed could reverse it. To do this, they used a well-studied drug called P7C3-A20 to restore NAD balance in the brain.

The results were striking. Not only did maintaining NAD levels prevent Alzheimer’s from developing in mice, but starting treatment later, after the disease was already advanced, allowed the brain to repair the main pathological damage caused by the genetic mutations. In both mouse models, cognitive abilities were fully restored.

What Is NAD In Alzheimer’s?

In Alzheimer’s disease, NAD, short for nicotinamide adenine dinucleotide, is an essential coenzyme whose levels naturally decline with age. This decline disrupts energy production, mitochondrial health, DNA repair, and the ability of neurons to withstand stress. Research suggests that increasing NAD levels, often through precursors such as nicotinamide riboside, may reverse Alzheimer’s-related damage, improve memory, and correct abnormal RNA processing in animal models. Because of this, NAD has become a major area of focus for developing new Alzheimer’s therapies, according to the National Institutes of Health.

Why NAD Is Important In Alzheimer’s

• Energy and Mitochondria: NAD is necessary for producing ATP, the cell’s main energy source, and for keeping mitochondria functioning properly, both of which are critical for healthy brain cells.
• Cellular Stress: NAD supports neurons in responding to and surviving stress. When NAD levels fall in Alzheimer’s, these protective mechanisms weaken.
• DNA Repair: NAD is involved in repairing DNA damage, which increases as amyloid-beta accumulates in the brain. Low NAD levels interfere with this repair process.
• RNA Splicing: Emerging research shows that NAD may help correct faulty RNA splicing events linked to Alzheimer’s. This process may involve a protein called EVA1C and could contribute to improved memory and better clearance of harmful proteins.

Next Steps Toward Human Trials

The findings also pave the way for further research and eventual testing in people. The technology behind the treatment is currently being developed for commercial use by Glengary Brain Health, a Cleveland-based company co-founded by Dr. Pieper.

“This recovery-based treatment approach now needs to be tested in carefully designed clinical trials to see if the benefits seen in animals can be replicated in humans,” Pieper said.

He added that future laboratory work will focus on identifying which components of brain energy balance matter most for recovery, exploring additional strategies that could complement this approach, and determining whether similar methods could work for other long-term, age-related neurodegenerative diseases as well.